FDA Guidance Would Transcend Traditional Three-Batch Validation
This article was originally published in The Gold Sheet
The rote three-batch approach to process validation would be history if industry adheres to a guidance document an FDA working group is drafting
You may also be interested in...
US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. Meanwhile, vaccine developers face challenge of when to change antigens to get the best results, NIH’s Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.
Agency’s struggle to meet user fee commitments despite travel restrictions expected to worsen as pandemic continues into 2021.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.